CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$297.50

08 Dec
2022

-1.690

OPEN

$300.38

-0.56%

HIGH

$300.55

423,055

LOW

$296.84

TARGET
$327.033 9.9% upside
Franking for last dividend paid out: 10%
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . OCC . ACW . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . MAP . CAU . OPT . ANP . TRP . BIO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY23
Forecast		 FY24
Forecast
EPS (cps) 787.2 xxx
DPS (cps) 365.5 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 37.9 xxx
Dividend Yield 1.2% xxx
Div Pay Ratio(%) 46.4% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.17%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.09

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 167.66c (franking 10%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx663.3
DPS All xxxxxxxxxxxxxxx318.1
Sales/Revenue xxxxxxxxxxxxxxx14,469.4 M
Book Value Per Share xxxxxxxxxxxxxxx4,400.8
Net Operating Cash Flow xxxxxxxxxxxxxxx3,624.8 M
Net Profit Margin xxxxxxxxxxxxxxx21.49 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx19.21 %
Return on Invested Capital xxxxxxxxxxxxxxx13.24 %
Return on Assets xxxxxxxxxxxxxxx9.51 %
Return on Equity xxxxxxxxxxxxxxx19.21 %
Return on Total Capital xxxxxxxxxxxxxxx14.56 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx704.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

10/11/2022

1

Upgrade to Outperform from Neutral

$310.00

4.20%

Credit Suisse examines the September-quarter results for CSL's offshore comps and finds Seqirus and Behring to have improved marginally but Vifor remains weak.

The broker upgrades CSL's EPS forecasts 1% to 2% accordingly.

Target price rises to $310 from $305.

Rating upgraded to Outperform from Neutral, the broker expecting the market will focus in on Behring's strong growth in plasma collections.

FORECAST
Credit Suisse forecasts a full year FY23 dividend of 359.81 cents and EPS of 779.82 cents.
Credit Suisse forecasts a full year FY24 dividend of 474.48 cents and EPS of 1000.57 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CSL STOCK CHART

FNArena News on CSL

1
In Brief: Insurers, Healthcare, Contractors, Classifieds, Retail 

Dec 09 2022 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Dec 01, 2022

Dec 01 2022 - Daily Market Reports
3
Rudi’s View: Regrets, 2022 Delivered A Few

Dec 01 2022 - Rudi's View
4
Australian Broker Call *Extra* Edition – Nov 30, 2022

Nov 30 2022 - Daily Market Reports
5
Rudi’s View: Preparing For Bear Phase II

Nov 24 2022 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Actinogen Medical

Nov 30 2022 - Small Caps
2
Dr Boreham’s Crucible: Qbiotics Group

Nov 09 2022 - Small Caps
3
Dr Boreham’s Crucible: Pharmaxis

Oct 05 2022 - Small Caps
4
Brokers Review Prospects For CSL

Sep 30 2022 - Australia
5
Dr Boreham’s Crucible: Inoviq Ltd

Sep 19 2022 - Small Caps
6
CSL: Offering Buying Opportunity

Sep 13 2022 - Technicals
7
Dr Boreham’s Crucible: Vaxxas Pty Ltd

Sep 07 2022 - FYI
8
Dr Boreham’s Crucible: Telix Pharmaceuticals

Aug 22 2022 - Small Caps
9
Dr Boreham’s Crucible: Orthocell

Jul 26 2022 - Small Caps
10
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals